

CRYOcheck™ 

dRVTT SCREENING REAGENT

LA CHECK™

Intended Use

CRYOcheck LA Check is a dilute Russell's Viper Venom Time (dRVVT) reagent intended to screen for the presence of lupus anticoagulants (LA) in citrated human plasma.

Summary and Principle

LA are autoantibodies of the IgG and IgM types that are specifically directed against negatively charged phospholipids, such as phosphatidylinositols and phosphatidylserines, or complexes of phospholipids with either β 2-glycoprotein-1 or clotting factors such as prothrombin. They occur in various clinical conditions, especially autoimmune diseases¹. LA have traditionally been detected using phospholipid sensitive in vitro clotting tests, such as the activated partial thromboplastin time (APTT), kaolin clotting time (KCT), and dRVVT². The dRVVT was introduced in 1986 and showed improved sensitivity to LA over the APTT partially due to a reduced phospholipid concentration³.

LA are usually indicated by a prolonged clotting time result that is not corrected by mixing patient plasma with normal plasma. The correction of a prolonged result by the addition of phospholipids to the plasma is a more specific characteristic of LA³.

LA prolong phospholipid-sensitive clotting tests; however, they are paradoxically associated with thrombotic problems⁴. LA are a common cause of unexplained prolonged APTTs and need to be carefully distinguished from idiopathic antibodies against factor VIII associated with bleeding.

LA are now considered to be a significant risk factor in patients with otherwise unexplained thrombosis and are often present in women who have recurrent fetal loss^{4,5}. They are also associated with a variety of hemostatic problems such as thrombocytopenia and neurological disorders⁶.

Russell's viper venom directly activates factor X, bypassing factor VII of the extrinsic pathway and the contact and antihemophilic factors of the intrinsic pathway. Therefore, dRVVT tests are more specific for LA than APTTs as they are not affected by contact factor abnormalities or by factor VIII deficiencies or antibodies³.

Reagents

CRYOcheck LA Check contains Russell's viper venom, phospholipids, anti-heparin agents, calcium, buffers, stabilizers, sodium azide, and green dye.



Sodium azide may react with lead and copper plumbing to form highly explosive metal compounds. Ensure proper disposal of reagent according to federal, state, and local regulations.

Storage and Handling

When stored at -40 to -80 °C, CRYOcheck LA Check is stable to the end of the month indicated on the product packaging.

Thaw each vial at 37 °C (± 1 °C) in a waterbath. **The use of a dry bath or heating block for thawing is not recommended.** Thawing times are important and should be strictly adhered to. The use of a timer is recommended. Refer to the Thawing Table for recommended thawing times based on aliquot size. Allow thawed plasma to acclimate to room temperature (18 to 25 °C) and invert gently prior to use.

Thawing Table	
Aliquot Size	37 °C (± 1 °C) Waterbath
1.0 mL	4 minutes
3.0 mL	6 minutes

CRYOcheck LA Check may be used for up to 48 hours after thawing, if capped in the original vial and maintained at 2 to 8 °C. Allow refrigerated reagent to acclimate to room temperature (18 to 25 °C) and invert gently prior to use. **Thawed material may be refrozen once and stored at -20 °C for up to one month.**

Availability

Product	Catalog #	Format
LA Check	CHK-10	25 vials x 1.0 mL
	CHK80-10	80 vials x 1.0 mL
	CHK50-30	50 vials x 3.0 mL

Instruments

Each lab should prepare the local instrument in accordance with the manufacturer's instructions for use.

Procedure

After thawing and preparing CRYOcheck LA Check, use in accordance with established laboratory procedures.

Materials Provided

- CRYOcheck LA Check

Materials Required but not Provided

- Waterbath capable of maintaining 37 °C (± 1 °C)
- Coagulation instrument or assay system

- Quality control material (e.g. *CRYOcheck* Lupus Positive Control, *CRYOcheck* Weak Lupus Positive Control)
- 12 mm x 75 mm glass test tubes
- Plastic disposable pipettes
- Volumetric pipette
- Timer
- Stopwatch

Specimen collection and Preparation

Patient samples should be collected into 105 - 109 mmol/L sodium citrate dihydrate anticoagulant (3.2%) in a ratio of 9 parts blood to 1 part anticoagulant. Patient plasma is derived by centrifugation at 1500 x g for 15 minutes in order to achieve platelet-poor plasma (<10,000 platelets/ μ L) and should be tested within four hours of collection when maintained at 2 to 4 °C in accordance with CLSI guidelines⁷. If samples are to be frozen before testing, plasmas should be centrifuged a second time, and stored at -20 °C or below.

Manual Method – Tilt Tube

1. In a 37 °C (\pm 1 °C) waterbath, prewarm a slight excess of *CRYOcheck* LA Check allowing 200 μ L per test.
2. Dispense 200 μ L of test plasma into a test tube and warm for one minute at 37 °C (\pm 1 °C).
3. Add 200 μ L of prewarmed *CRYOcheck* LA check to the plasma and simultaneously initiate the clot timer. Record clotting times in seconds.
4. Repeat for duplicate test values and report the average of these as the result.

Automated Methods

Reagent preparation instructions and instrument settings for variety of analyzers are available upon request from Precision BioLogic.

Results

If the *CRYOcheck* LA Check clotting time is within the laboratory- established normal reference range, further testing for LA may not be necessary. If the *CRYOcheck* LA Check clotting time result is prolonged (i.e. more than three standard deviations (SD) longer than the mean of the laboratory-established normal reference range), the result should be investigated further. A prolonged result may be indicative of:

- the presence of LA
- factor II, V, or X deficiency
- oral anticoagulant therapy (OAT)

If the *CRYOcheck* LA Check result is prolonged, *CRYOcheck* LA Sure™ confirmatory test (Precision BioLogic Catalog No. SUR-10) should be performed. Evidence of inhibitory activity can be shown using an additional mixing step of patient plasma and pooled normal plasma. Failure of the mixture to correct the original prolonged clotting time is evidence of a possible inhibitor⁸. This step may be incorporated into the initial *CRYOcheck* LA Check screening procedure.

In accordance with the SSC Subcommittee for the Standardization of LA guidelines⁸, results should be compared to other established LA tests performed on the same sample, since no single assay can guarantee, with certainty, that LA is present or absent.

Quality Control

Each laboratory should establish its own quality control (QC) ranges using acceptable statistical methods. These QC ranges may then be used to monitor and validate the integrity of the test system⁹. For all coagulation tests, the laboratory must include at least two levels of control for every eight hours of operation and any time a change in reagents occurs¹⁰.

Commercial lyophilized quality control plasmas containing unspecified levels of citrate and platelets are not recommended as they may give erroneous results^{11, 12}

Limitations of the Procedures

Patients with deficiencies of factors II, V, or X or patients on anti- vitamin K therapy may exhibit prolonged *CRYOcheck* LA Check times. Although normal plasma mixing studies may correct for these deficiencies, published data has demonstrated that further dilution of weak non-specific inhibitors such as a lupus anticoagulant can occur and produce false-negative results in dRVVT procedures¹³. *CRYOcheck* LA Check results on plasmas subjected to mixing studies should be interpreted with care.

CRYOcheck LA Check is unaffected by heparin levels up to 1.0 unit/mL. Plasmas containing heparin levels greater than 1.0 unit/mL may give false-positive results and should not be tested with this reagent.

Plasma samples with visible hemolysis should not be used due to possible clotting factor activation and endpoint measurement interference⁷. Icteric or lipemic samples may also interfere with endpoint determination on some optical instruments⁷.

Expected Values

In a study of 20 healthy males and females using a Diagnostica Stago ST4[®] analyzer, a *CRYOcheck* LA Check normal reference range (3 SD confidence interval) of 25.7 - 46.0 seconds was established. These values should be used as a guide only. Each laboratory should establish their own normal reference range.

Performance Characteristics










In precision studies over 48 hours at 2 to 8 °C with *CRYOcheck* Lupus Positive Control plasma on a Diagnostica Stago ST4[®] analyzer, *CRYOcheck* LA Check exhibited an overall coefficient of variation (CV) of 3.26%.


An $R^2=0.969$ was derived in a correlation study using Gradipore LA Screen™ dRVVT screening test involving OAT patient plasmas (n=15), known LA positive samples (n=12), and plasmas with depleted levels of factors II (n=3), V (n=3), and X (n=3).

Bibliography

1. Arnout J. Antiphospholipid syndrome: Diagnostic aspects of lupus anticoagulants. *J Thromb Haemost* 2001; 86(1):83-91.
2. Triplett DA, Brandt JT. Laboratory identification of the lupus anticoagulant. *Br J Haematol* 1989; 73(2):139-142.
3. Thiagarajan P, Pengo V, Shapiro SS. The use of the dilute Russell's Viper Venom Time for the diagnosis of lupus anticoagulants. *Blood* 1986; 68(4):869-874.
4. Love PE, Santoro SA. Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. *Ann Intern Med* 1990; 112(9):682-698.
5. Feinstein DI. Lupus anticoagulant, thrombosis and fetal loss. *N Engl J Med* 1985; 313:1348-1350.
6. Harris EN, Asherson RA, Hughes GRV. Antiphospholipid antibodies – autoantibodies with a difference. *Ann revs Med* 1988; 39:261-271.
7. Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based coagulation Assays and Molecular Hemostasis Assays; Approved Guideline – Fifth Edition; CLSI, H21-A5 Vol. 28 No. 5, 2008.
8. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, De Groot PG; Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation committee of the International Society on Thrombosis and Haemostasis. *J Thromb Haemost*. 2009;7(10):1737-1740.
9. Cembrowski GS, Carey RN. Laboratory quality management. Chicago: ASCP Press; 1989. p. 166-171.
10. CLIA 2004 – Code of Federal Regulations, 42CFR493.1269, 2004.
11. Adcock DM, Kressin DC, Marlara RA. Effect of 3.2% vs. 3.8% sodium citrate concentration on routine coagulation testing. *Am J Clin Pathol* 1997; 107(1):105-110.
12. Hirst CF, Poller L. The cause of turbidity in lyophilized plasmas and its effects on coagulation tests. *J Clin Pathol* 1992; 45(8):701-703.
13. Thom J, Ivey L, Eikelboom J. Normal plasma mixing studies in the laboratory diagnosis of lupus anticoagulant. *J Thromb Haemost* 2003; 1: 2689-2691.

Symbols Used

	In vitro diagnostic medical device		Biological risks
	Batch code		Manufacturer
	Catalogue number		Authorized representative in the European Community / European Union
	Use by	Rx ONLY	For prescription use only
	Temperature limit		Consult electronic instructions for use



European Authorized Representative (Regulatory affairs only)
Emergo Europe—Prinsessegracht 20, 2514 AP The Hague, The Netherlands



Precision BioLogic Inc.
140 Eileen Stubbs Avenue | Dartmouth, Nova Scotia | B3B 0A9 | Canada

Tel: 1.800.267.2796 / +1.902.468.6422

Fax: 1.800.267.0796 / +1.902.468.6421

www.precisionbiologic.com